- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00754403
Efficacy of Pioglitazone and Fortamet Combination Therapy in Subjects With Type 2 Diabetes
A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Effects on Glycemic Control With Concomitantly Administered Pioglitazone HCl and Metformin HCl Extended Release (Fortamet®) in Subjects With Type 2 Diabetes
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Pioglitazone (ACTOS®) is a member of a class of oral antidiabetic agents known as thiazolidinediones. The insulin-sensitizing actions of thiazolidinediones are at least partially mediated through the peroxisome proliferator-activated receptor gamma. These receptors are found primarily in adipocytes, vascular endothelial cells, monocytes, hepatocytes, and to a lesser extent myocytes.
Metformin was developed as an extended-release formulation of metformin hydrochloride and designed for once-a-day oral administration. Metformin is an antihyperglycemic agent, which improves glucose tolerance in patients with, type 2 diabetes, lowering both basal and postprandial plasma glucose.
On 15 July 1999, the FDA approved pioglitazone for use as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. Pioglitazone is indicated for monotherapy and for use in combination with sulfonylureas, metformin, or insulin when diet and exercise plus the single agent do not result in adequate glycemic control. On 26 November 2003, the FDA approved the combined use of pioglitazone with metformin.
This study is designed to evaluate the effect on glycemic control when pioglitazone and metformin are taken together. Individuals participating in this study will provide written informed consent and will be required to commit to a screening visit and approximately 5 additional visits at the study center. Study participation is anticipated to be about 31 weeks (or approximately 8 months). Multiple procedures will occur at each visit which may include fasting, blood collection, urine collection, physical examinations and electrocardiograms.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study
- Diagnosed with type 2 diabetes and must have received appropriate counseling on lifestyle modification for type 2 diabetes including diet and exercise.
- If taking metformin monotherapy or metformin and sulfonylurea combination therapy, has a glycosylated hemoglobin greater than or equal to 7.5% and less than or equal to 9.0% at screening and randomization.
- If naïve or taking sulfonylurea monotherapy has an glycosylated hemoglobin greater than or equal to 8.5% and less than or equal to 10.0% at screening and greater than or equal to 7.5% and less than or equal to 9.0% at randomization.
Exclusion Criteria
- Has type 1 diabetes mellitus
- Currently taking any thiazolidinedione or have taken any thiazolidinedione within 12 weeks prior to screening
- Has congestive heart failure; has a triglyceride level greater than 500 mg per dL
- Diastolic blood pressure greater than 100 mmHg or a systolic pressure greater than 160 mmHg
- Body mass index greater than or equal to 42 kg/m2 (weight /height2)
- Alanine transaminase level greater than or equal to 2.5 times the upper limit of normal, active liver disease, or jaundice.
- Male subjects who have a serum creatinine level greater than or equal to 1.5 mg per dL; female subjects who have a serum creatinine level greater than or equal to 1.4 mg per dL at the screening visit and at randomization.
- Currently using insulin or has used insulin 3 months prior to Screening
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis with or without coma.
Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:
- Chronically used oral or parenteral glucocorticoids (eg, prednisone, cortisone, hydrocortisone, dexamethasone)
- Niacin greater than 200 mg per day, including niacin-containing products such as Advicor - 3 months prior to screening and during the study
- Chronically used steroid-joint injections - 3 months prior to screening and during the study
- Thiazolidinediones - 3 months prior to screening and during the study
- Insulin - 3 months prior to screening
- Other oral antidiabetic medications (eg, nateglinide [Starlix], acarbose [Precose]) with the exception of sulfonylurea - 3 months prior to screening and during the study
- Metformin - Fortamet Stabilization and during the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pioglitazone 30 mg QD + Metformin 1000 mg QD
|
Pioglitazone 30 mg, tablets, orally, once daily and metformin 1000 mg, tablets, orally once daily for up to 16 weeks.
Other Names:
|
Active Comparator: Metformin 1000 mg QD
|
Pioglitazone placebo-matching tablets, orally, once daily and metformin 1000 mg, tablets, orally once daily for up to 16 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from randomization in Glycosylated Hemoglobin
Time Frame: Final Visit
|
Final Visit
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from randomization in Fasting Plasma Glucose
Time Frame: Final Visit
|
Final Visit
|
Change from randomization in Insulin
Time Frame: Final Visit
|
Final Visit
|
Change from randomization in Pro-Insulin
Time Frame: Final Visit
|
Final Visit
|
Change from randomization in Homeostasis Model Assessment
Time Frame: Final Visit
|
Final Visit
|
Change from randomization in Triglycerides
Time Frame: Final Visit
|
Final Visit
|
Change from randomization in Total Cholesterol
Time Frame: Final Visit
|
Final Visit
|
Change from randomization in Low-Density Lipoprotein Cholesterol
Time Frame: Final Visit
|
Final Visit
|
Change from randomization in high-density Lipoprotein Cholesterol
Time Frame: Final Visit
|
Final Visit
|
Change from randomization in Lipid Fractionation
Time Frame: Final Visit
|
Final Visit
|
Change from randomization in High Sensitivity C-Reactive Protein
Time Frame: Final Visit
|
Final Visit
|
Change from randomization in Creatine Phosphokinase
Time Frame: Final Visit
|
Final Visit
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 01-05-TL-OPIXT-010
- U1111-1114-2423 (Registry Identifier: WHO)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
Meir Medical CenterCompletedDiabetes Mellitus Type 2 | Diabetes Mellitus, Non-insulin Dependant | Diabetes Mellitus, on Oral Hypoglycemic Treatment | Adult Type Diabetes MellitusIsrael
-
Medical College of WisconsinMedical University of South CarolinaCompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type IIUnited States
-
Hanmi Pharmaceutical Company LimitedUnknownType2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Medical College of WisconsinMedical University of South Carolina; National Institute of Diabetes and Digestive...Active, not recruitingDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Medical College of WisconsinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
Clinical Trials on Pioglitazone and metformin
-
Huazhong University of Science and TechnologyHubei Xinhua Hospital; Wuhan Iron and Steel Workers' Hospital; Wuhan Pu-Ai HospitalCompletedDiabetes Mellitus, Type 2China
-
University of MinnesotaNot yet recruitingOral LeukoplakiaUnited States
-
King Edward Medical UniversityCompleted
-
Postgraduate Institute of Medical Education and...Council of Scientific and Industrial Research, IndiaWithdrawn
-
Xiang Guang-daCompletedEndothelial Function | LVM | Type 2 Diabetic Patients With IHDChina
-
Khyber Medical University PeshawarCompletedPolycystic Ovarian SyndromePakistan
-
Daiichi Sankyo, Inc.CompletedDiabetes Mellitus, Type 2United States
-
Bing HeActive, not recruitingPolycystic Ovary SyndromeChina
-
Dow University of Health SciencesUnknownHyperandrogenism | Menstrual IrregularitiesPakistan
-
TakedaCompleted